Despite improved access to early revascularization and contemporary optimal medical therapy after MI (with novel antiplatelet agents, β-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and aldosterone antagonists, which are clearly associated with reduced mortality after MI), sudden death continues to be the most common mode of death after MI. This evidence concerns the gene ACE and myocardial infarction.